Ginkgo Bioworks Holdings

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ginkgo Bioworks reports strong Q4 earnings, eyes biopharma growth

Ginkgo Bioworks reports strong financial performance and strategic growth in Q4 2022, focusing on downstream value share and biosecurity leadership.
While facing challenges with negative EBITDA, the company aims to drive efficiency, expand biosecurity initiatives, and capitalize on opportunities in biopharma and API manufacturing.
With a solid financial foundation, Ginkgo is well-positioned to leverage its expertise in programming cells and proprietary protein sequences for future growth and market expansion.

Ginkgo Bioworks reports strong Q1 growth and eyes global expansion

Ginkgo Bioworks showcased strong performance in Cell Engineering and Biosecurity revenue, emphasizing platform improvement and strategic partnerships.
While facing challenges in enterprise sales and operating expenses, the company is well-positioned for growth through international biosecurity expansion and biopharma focus.
Opportunities lie in global biosecurity initiatives, biopharma sales pipeline, and persistent monitoring programs, signaling a promising future for Ginkgo.

Ginkgo Bioworks posts robust Q2 results, eyes revenue diversification

Ginkgo Bioworks reported strong growth in revenue and active programs, with a focus on operational efficiencies and customer relationships.
Transitioning to success-based pricing models and task-specific data training positions the company for revenue diversification and enhanced customer value.
While facing market challenges and funding constraints, Ginkgo is strategically expanding its offerings and driving towards profitability through operational enhancements.

Ginkgo Bioworks reports strong Q3 performance and biosecurity opportunities

Ginkgo Bioworks reports strong performance with revenue growth and increased active programs.
The company's strengths lie in AI progress, diverse customer base, and biosecurity applications.
Challenges include deal timing, competitive positioning, and managing operational expenses.
Opportunities include tech licensing deals, AI-driven efficiency, and synergies between biosecurity and cell engineering.

Ginkgo Bioworks navigates revenue challenges with strategic growth initiatives

Ginkgo Bioworks faces revenue challenges from program dynamics but is strategically positioned for growth through R&D investments and partnerships.
The company's focus on innovation, efficiency, and biosecurity infrastructure underscores its commitment to leading in biotech R&D.
Opportunities in expanding partnerships, enhancing automation technology, and standardizing interfaces signal a promising path for Ginkgo's future growth.
Despite short-term revenue setbacks, Ginkgo's strategic initiatives and industry positioning bode well for long-term success and market leadership.

Ginkgo Bioworks targets EBITDA breakeven by 2026 amid revenue challenges

Ginkgo Bioworks is navigating challenges in revenue growth while focusing on cost reductions and operational efficiency to achieve EBITDA breakeven by 2026.
The company's strategic shift towards biopharma and bioAg sectors showcases flexibility and growth potential in serving large companies with research budgets.
Introduction of 'Lab Data as a Service' and focus on streamlining workflows present opportunities for scalability and revenue enhancement.
Despite challenges in revenue outlook and restructuring efforts, Ginkgo remains committed to operational success and financial sustainability.

Ginkgo Bioworks advances cost-saving goals amidst revenue challenges

Ginkgo Bioworks progresses towards financial targets amidst revenue challenges and aggressive cost-saving measures.
Strategic focus on automation, biosecurity, and revenue diversification positions the company for future growth.
Challenges include revenue decline, employee impact from layoffs, and balancing cost reduction with innovation.
Opportunities lie in new revenue streams, margin accretive initiatives, and market differentiation through mission-driven approach.

Ginkgo Bioworks reports mixed Q3 results, focuses on growth strategies

Ginkgo Bioworks showed strength in cost-cutting, revenue generation, and strategic focus, despite a negative adjusted EBITDA.
Challenges include financial pressures, margin concerns, and potential risks in resource utilization and funding stability.
Opportunities lie in new offerings, AI capabilities, market expansion, and revenue scale for improved profitability.
Management's emphasis on cost reduction, revenue growth, and innovation positions the company for long-term success and sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BOSTON, Oct. 20, 2021 /PRNewswire/ -- Ginkgo Bioworks Inc. (NYSE: DNA) ("Ginkgo"), which is building the leading horizontal platform for cell programming, announced today that management is scheduled to present at the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 3:00p.m. Eastern Time.

Ginkgo Bioworks Announces Participation in Jefferies Gene Therapy/Editing Summit

Today, a bullish analyst price target placed on Ginkgo Bioworks has sent DNA stock on a nice ride as investors pile into this growth play. The post Ginkgo Bioworks Price Predictions: Why One Analyst Thinks Hard-Hit DNA Stock Can Hit $14.50 appeared first on InvestorPlace.

Ginkgo Bioworks Price Predictions: Why One Analyst Thinks Hard-Hit DNA Stock Can Hit $14.50

Wall Street is waxing bullishly on this synbio start-up.

Why Shares of Gingko Bioworks Are Skyrocketing Today

San Francisco, California--(Newsfile Corp. - October 13, 2021) -  Hagens Berman urges Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) investors with significant losses to submit your losses now.Visit: www.hbsslaw.com/investor-fraud/DNA Contact An Attorney Now: DNA@hbsslaw.com 844-916-0895Ginkgo Bioworks Holdings, Inc. (DNA) Investigation: Ginkgo Bioworks is a synthetic biology company that uses a cell programming platform called "Ginkgo Foundry" to assist companies in finding more effective ways to create products.The company...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Ginkgo Bioworks (DNA) Investors to Contact Firm's Attorneys Now, Firm Investigating Possible Securities Law Violations

If the latest short-seller attack on Ginkgo Bioworks has you nervous about synthetic biology, consider the industry leader.

Never Mind Ginkgo Bioworks' Drama -- This Synthetic Biology Stock Is Still a Buy

Ginkgo Bioworks (DNA) stock is doing well on Tuesday as it recovers with new coverage from an analyst with a bull stance. The post DNA Stock: The Bull Call That Has Ginkgo Bioworks Bouncing Back After Last Week's “Scam” Accusation appeared first on InvestorPlace.

DNA Stock: The Bull Call That Has Ginkgo Bioworks Bouncing Back After Last Week's “Scam” Accusation

Boston, Massachusetts--(Newsfile Corp. - October 12, 2021) - Block & Leviton is investigating Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) for potential securities law violations. Investors who have lost money in their Ginkgo Bioworks Holdings, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/dna.What is this all about?Earlier today, short seller Scorpion Capital released a report alleging that Ginkgo Bioworks Holdings is a "colossal...

GINKGO BIOWORKS INVESTIGATION: Block & Leviton Is Investigating Ginkgo Bioworks Holdings For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm

Soaring Eagle Acquisition Corp

Radnor, Pennsylvania--(Newsfile Corp. - October 12, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo") f/k/a Soaring Eagle Acquisition Corp. (NASDAQ: SRNG) ("Soaring Eagle").Ginkgo develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals...

Ginkgo Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Ginkgo Bioworks Holdings, Inc. Investors

Beam Therapeutics

Signify Health

All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.

Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought

Cathie Wood-led Ark Invest on Friday snapped up more shares in Ginkgo Bioworks Holdings Inc (NYSE: DNA) on the dip. The popular money manager's investment firm snapped up 1.53 million shares — estimated to be worth $15.86 million — in the synthetic biology stock that was hit hard last week by two back-to-back short-seller reports that called the company a “colossal scam” and “a scheme.

Cathie Wood's Ark Invest Piles Up Another $15.8M In Gingko On Dip Amid Short-Seller Allegations

Boston, Massachusetts--(Newsfile Corp. - October 9, 2021) - The Thornton Law Firm alerts investors that it is investigating Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) for potential securities violations. Investors who currently own shares or options of DNA may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Ginkgo for more information. Investors may also email investors@tenlaw.com or call 617-531-3917. FOR MORE INFORMATION: www.tenlaw.com/cases/GinkgoOn October 6, 2021, short seller Scorpion Capital released a report...

DNA Investor Alert: Thornton Law Firm Announces Investigation

RADNOR, Pa., Oct. 8, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP is currently investigating potential violations of the federal securities laws on behalf of shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo") f/k/a Soaring Eagle Acquisition Corp. (Nasdaq: SRNG) ("Soaring Eagle").

Ginkgo Investigation Alert: Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Investors

New York, New York--(Newsfile Corp. - October 8, 2021) -  Levi & Korsinsky notifies investors that it has commenced an investigation of Ginkgo Bioworks Holdings, Inc. ("Ginko Bioworks" or the "Company") (NYSE: DNA) concerning possible violations of federal securities laws.On October 6, 2021, Scorpion Capital published a report about Ginkgo alleging that it is a "colossal scam." It describes the Company's business model is a "shell game," and that the company is highly dependent on...

EQUITY ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Ginkgo Bioworks Holdings, Inc.

NEW YORK, Oct. 7, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) resulting from allegations that Ginkgo may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Ginkgo securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

DNA BREAKING NEWS: ROSEN, LEADING INVESTOR COUNSEL, Encourages Ginkgo Bioworks Holdings, Inc. Investors with Losses to Inquire About Class Action Investigation - DNA

Los Angeles, California--(Newsfile Corp. - October 7, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or "the Company") (NYSE: DNA) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Ginkgo is the subject of a report published by Scorpion...

ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Ginkgo Bioworks Holdings, Inc. and Encourages Investors with Losses to Contact the Firm

Boston, Massachusetts--(Newsfile Corp. - October 7, 2021) - The Thornton Law Firm alerts investors that it is investigating Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) for potential securities violations. Investors who currently own shares or options of DNA may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Ginkgo for more information. Investors may also email investors@tenlaw.com or call 617-531-3917. FOR MORE INFORMATION: www.tenlaw.com/cases/GinkgoOn October 6, 2021, short seller Scorpion Capital released a report...

Thornton Law Firm Announces Investigation Into DNA

RADNOR, Pa.--(BUSINESS WIRE)---- $DNA--Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Investors

DNA Investigation Alert:  Kessler Topaz Meltzer & Check, LLP is Investigating Securities Fraud Claims on Behalf of Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) Investors

A couple of ARK Invest exchange-traded funds run by ETF star Cathie Wood made a huge buy on Wednesday.

Cathie Wood's ARK Invest Buys Over 8 Million Shares of Ginkgo Bioworks

Cathie Wood-led Ark Invest on Wednesday snapped up shares in Ginkgo Bioworks Holdings Inc (NYSE: DNA) on the day the synthetic biology company stock was hit hard by two back-to-back short-seller reports that called the company a “colossal scam” and “a scheme.” The popular money manager bought 8.26 million shares — estimated to be worth $87.5 million — in the Boston, Massachusetts-based biotech company.

Cathie Wood Sells $49.4M In Tesla And Buys $87.5M In Ginkgo Bioworks On Dip As Stock Becomes Target Of Short Sellers

MILWAUKEE, Oct. 6, 2021 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Ginkgo (NYSE:DNA).  The investigation results from inaccurate statements Ginkgo may have made regarding its business operations and prospects.

Ademi LLP Investigates Claims of Securities Fraud against Ginkgo Bioworks Holdings, Inc.

LOS ANGELES--(BUSINESS WIRE)---- $DNA #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) (NYSE: DNA) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Ginkgo investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securi

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Ginkgo Bioworks Holdings, Inc. (DNA) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)---- $DNA #investors--The Law Offices of Frank R. Cruz Announces Investigation of Ginkgo Bioworks Holdings, Inc. (DNA) on Behalf of Investors

The Law Offices of Frank R. Cruz Announces Investigation of Ginkgo Bioworks Holdings, Inc. (DNA) on Behalf of Investors

Atlanta, Georgia--(Newsfile Corp. - October 6, 2021) -  Holzer & Holzer, LLC is investigating whether Ginkgo Bioworks Holdings, Inc. ("Ginkgo" or the "Company") (NYSE: DNA) complied with federal securities laws. On October 6, 2021, Scorpion Capital released a report alleging, among other things, the Company is highly dependent on related party transactions. On this report, the price of the Company's stock declined.If you purchased Ginkgo stock and suffered a substantial loss on that investment, you...

SHAREHOLDER ALERT: Investigation of Ginkgo Bioworks Holdings, Inc. Announced by Holzer & Holzer, LLC

BENSALEM, Pa.--(BUSINESS WIRE)---- $DNA #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Ginkgo Bioworks Holdings, Inc. (“Ginkgo” or the “Company”) (NYSE: DNA) investors concerning the Company's possible violations of federal securities laws. On October 6, 2021, Scorpion Capital published a 175-page research report alleging that Ginkgo Bioworks is a "colossal scam" and that its business model is a "shell game." According to the report, Ginkgo Bioworks is highly dependent on relate

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Ginkgo Bioworks Holdings, Inc. (DNA) on Behalf of Investors

Today, Ginko Bioworks and DNA stock are firmly in the sights of short-sellers as various claims are made about an elaborate fraud underway. The post DNA Stock: 7 Things to Know About the Short Report Hammering Ginkgo Bioworks appeared first on InvestorPlace.

News for Ginkgo Bioworks Holdings Stock (DNA)